-
First-line zongertinib demonstrates durable responses in HER2-mutant NSCLC
Brett Bade, MD, and Katie Smith, MD, said the expansion of targeted therapies for lung cancer is an important advance, while noting that questions remain regarding the drug’s role in the first-line setting.
Recent News
-
Impossible choices: Goal-concordant care in the ICU
Clinicians should approach discussions about goal-concordant care with curiosity, humility, and responsibility, for the benefit of both the patient and their family.
-
Recognizing OSA in women: The peri-operative opportunity
OSA in women continues to be underrecognized because it often presents differently than the classic OSA phenotype that has shaped clinical recognition for decades.
-
How social determinants of health impact lung cancer care
Patient outcomes in lung cancer care vary greatly by race, geography, income, and access to care. Learn how experts are addressing disparities through education, screening, and culturally responsive and personalized care.
-
Setidegrasib demonstrates durable responses in KRAS G12D-mutant NSCLC
Coauthor Anup Kasi, MD, MPH, said the study represents an important step forward in the development of KRAS G12D-targeted therapies.
-
Study links isoflavone intake to reduced COPD morbidity
Mariah K. Jackson, PhD, RDN, LMNT, said that while the research does not establish causality, nutrition is generally a safe, well-tolerated, and cost-effective strategy to improve respiratory health.
-
New portable, accurate TB test may broaden access
International TB specialist Alfred A. Lardizabal, MD, said he believes the development will empower resource-limited communities by bringing TB diagnostic capacity closer.
